Infant Bacterial Therapeutics

Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Pre-BLA meeting with FDA in Washington 29th October 2026

On 29th October 2026, IBT’s Pre-BLA (Pre-Biologics License Application) meeting with the FDA regarding IBP-9414, the company’s drug candidate, went ahead as planned in Washington, DC. The primary purpose of a pre-BLA meeting is alignment: confirming that the data package is adequate to avoid a “Refusal to File” (RTF) and ensure an efficient review. On the 29th, no RTFs were raised, but IBT expects to receive the FDA's formal meeting minutes by the end of November. 
Staffan Strömberg CEO at IBT says: “The meeting went well, and I am very pleased that FDA and IBT share the same position on what significant medical needs IBP-9414 targets to satisfy. We are hence continuing our work to submit our BLA as soon as possible.”

Datum 2026-11-02, kl 16:14
Källa MFN